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Metabolomics data are used to parameterize individual-specific kinetic models of metabolism to predict
medically relevant parameters underpinning disease states or outcomes.Advances in genome sequencing and
‘‘big data’’ analysis are facilitating sys-
tems-level approaches to clinical health-
care and disease detection (Belle et al.,
2015). In this context, genome-scale
models have been used to study meta-
bolic aspects of disease, but existing
modes of analysis often fail to establish
a mechanistic relationship between a
causative agent and an observed shift in
metabolism. In addition, one of the
most widely used modeling approaches
(constraint-based modeling) overlooks
important dynamic substrate-level mass
action and regulation. In this issue of
Cell Systems, Bordbar et al. (2015)
address these shortcomings with a sys-
tematic framework for constructing
genome-wide kinetic models personal-
ized for the metabolism of an individual.
They use their models in a proof-of-
concept application aimed at assessing
the suitability of a drug for different indi-
viduals based on their genomic and
phenotypic profiles. Lessons learned
from this study are potentially applicable
to many drug treatments with metabolic
side effects.
The roots of personalized models of hu-
man metabolism lie in the first global hu-
man metabolic network, called Recon 1,
introduced in 2007. This model was con-
structed by identifying metabolic en-
zymes annotated in the human genome
that could perform the biochemical func-
tions in known metabolic pathways. It
was created by aggregating knowledge
compiled over decades of scientific publi-
cations, and although specific to human
metabolism, it is not representative of
the specific processes that may occur in
any given cell type or individual.
Multiple efforts have tailored the reac-
tion content of a human metabolic
network to construct tissue- and cell-250 Cell Systems 1, October 28, 2015 ª2015type-specific metabolic models (Bordbar
and Palsson, 2012). Such models can
help assess host-pathogen interactions.
They have also been used to identify
metabolic shifts induced by malignancy,
identify drug targets to kill malignant cells
(Yizhak et al., 2015), and restore aberrant
metabolism to its ‘‘healthy’’ state (Yizhak
et al., 2013).
The same principles adopted for con-
structing tissue-specific models have
been co-opted to develop personalized
metabolic models. Individual-specific
transcriptomic, proteomic or metabolo-
mics information have been used to
constrainmetabolic pathways. The result-
ing model facilitates the study of relation-
ships between variations in individual
metabolism with a person’s response to
clinical treatment (e.g., a particular can-
cer-targeting drug) (Benson, 2015). These
efforts have been used to identify person-
alized drug targets (Agren et al., 2014) and
reveal potential off-targets effects of
drugs (Zielinski et al., 2015).
Bordbar et al. take a next step and use
metabolomics data from a pool of indi-
viduals in the context of a previously
described approach to kinetic modeling
of metabolism. Using an ensemble
modeling approach (Tran et al., 2008),
Bordbar et al. first constructed a baseline
ensemble of kinetic models of human
erythrocyte metabolism. Next, they re-
parameterized the kinetic information us-
ing data on 44 plasma and 69 intracellular
erythrocyte metabolites profiled in 24 in-
dividuals using multiple reaction moni-
toring mass spectrometry. Importantly,
this allowed the authors to study variation
between individuals in the dynamics of
metabolic processes.
Bordbar et al. use their models to
postulate a mechanism for the off-target-
ing effect (hemolytic anemia) of ribavirinElsevier Inc.drug in certain individuals having high
phosphoglycerate kinase activity. What
is quite remarkable is that the off-target
susceptible genotype was manifested
more clearly in the kinetic parameter
values rather than in the concentration of
metabolites bolstering the necessity for
kinetic modeling.
Future work could improve the predic-
tive capability of this line of analysis by
augmenting the metabolomics data used
by Bordbar et al. with additional omics in-
formation to parameterize the kinetic
models (Figure 1). Because cellular
metabolite levels have been shown to be
altered far less than pathway fluxes or
their corresponding enzyme activities
(Ishii et al., 2007), it would be useful to
capture individual variation in enzymes.
Notably, in the expectation-maximization
approach used by Bordbar et al. to esti-
mate kinetic parameters, enzyme levels
are assumed to be constant. One could
instead envision a two-stage approach
where first enzyme levels are updated
based on a carefully designed set of pro-
teomic and transcriptomicmeasurements
and then the expectation-maximization
approach is used to estimate parameters.
In addition, detailed substrate-level regu-
latory information, currently absent in the
framework of Bordbar et al. could help
improve the fidelity of prediction.
Ultimately, one would like to have
sufficient experimental information to
extract a single kinetic model from the
ensemble of models capable of accu-
rately predicting individual phenotypes
across multiple genetic perturbations
and/or drug exposures. Recent studies
such as the 100K wellness project
(Hood et al., 2015) have been tabulating
extensive genotypic and phenotypic
information of individuals. Such big
data compilations, along with detailed
Figure 1. Construction of Individual-Specific Kinetic Models of Metabolism
Incorporation of multi-omics information in the dynamic concentration balances in the form of 13C
metabolic flux data, baseline enzyme levels, metabolite concentrations as well as substrate level
regulation could enable the parameterization (left) and personalization (right) of kinetic models of
metabolism.
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Previewsdescriptions of metabolism, could pro-
vide the necessary tools in the future
for parameterizing large-scale person-
alized kinetic models for monitoring
individual health as well as suggestingpharmacological strategies compatible
with the individual genotype. This will
require careful parameterization of the
kinetic models and confirmation of the
proposed mechanisms of action.Cell Systems 1REFERENCES
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Two recent papers in Cell interpret lists of cancer genomic alterations in terms of how mutations rewire
interactome networks.The human genome project, conventional
positional cloning efforts, and genome-
wide association studies (GWAS), as
well as exome sequencing and full
genome sequencing of large numbers of
tumors, have identified a nearly complete
list of candidate human cancer genes. But
how these genomic variants, sometimes
referred to as the cancer ‘‘variome,’’ lead
to tumorigenesis remains obscure. Toaddress this issue, work by Creixell et al.
published in Cell describe new ap-
proaches for harnessing orthogonal data
to functionally annotate a subset of the
cancer variome (Creixell et al., 2015a;
Creixell et al., 2015b). More importantly,
these two papers put the cancer variome
in the context of signaling networks to
understand how individual cancer varia-
tions initiate network perturbations. Thesetools promise to advance our understand-
ing of mechanisms of tumorigenesis,
which in turn may provide leads for the
development of novel effective therapeu-
tic interventions.
Although lists of cancer mutations
are critical to understand the genetic
architecture of the cancer genome, it is
increasingly appreciated that complex
molecular networks and systems formed, October 28, 2015 ª2015 Elsevier Inc. 251
